Gastro-esophageal reflux disease (GERD) is mainly treated with proton pump inhibitor (PPI) drugs, or a Nissen fundoplication operation.
Recently, a device known as Endocinch has been developed to treat GERD. This is used to place sutures just below the esophagogastric junction (EGJ).
|Mean heartburn symptom score was reduced from 19.22 at baseline, to 7.5 at 12 months.|
This study, published in the January issue of Gut, evaluated the long term benefit of the Endocinch technique, in patients seen up to 12 months post procedure.
The team recruited 26 patients (mean age 39 years) with symptoms of GERD into the study, these patients received Endocinch therapy. Of these, 22 completed their 1-year follow-up.
Pre- and post-procedure assessments included symptom scoring (DeMeester), upper intestinal endoscopy, esophageal manometry and 24 hour esophageal pH, as well as completion of quality of life (QOL) questionnaires.
The research team found that the mean heartburn symptom score was reduced from 19.22 at baseline, to 7.5 at 12 months.
In addition, mean regurgitation score reduced from 2.27 at baseline, to 0.86 at 12 months.
Mean pH DeMeester acid score was reduced from 44.1, to 33.32 at 3 months post-procedure.
Furthermore, percentage upright acid exposure and number of reflux episodes were also reduced significantly.
The team also found that the use of PPIs was reduced by 64% at 12 months post-procedure.
All QOL assessments showed significant improvement.
Additionally, all transient post-procedure complaints resolved within 72 hours.
Dr Mahmood's team concluded, "The Endocinch procedure is an effective and safe outpatient procedure that offers GERD patients significant improvement in symptomatology, QOL, and reduced requirements for PPIs over at least a 1 year period".